Gabriella D. D'orazi-Orazi

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.

A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.

Journal: Journal of experimental & clinical cancer research : CR

Published: June 04, 2020

Correction to: Targeting hypoxia in tumor: a new promising therapeutic strategy.

Correction to: Targeting hypoxia in tumor: a new promising therapeutic strategy.

Journal: Journal of experimental & clinical cancer research : CR

Published: February 26, 2020

Targeting hypoxia in tumor: a new promising therapeutic strategy.

Targeting hypoxia in tumor: a new promising therapeutic strategy.

Journal: Journal of experimental & clinical cancer research : CR

Published: December 06, 2019

Quercetin Interrupts the Positive Feedback Loop Between STAT3 and IL-6, Promotes Autophagy, and Reduces ROS, Preventing EBV-Driven B Cell Immortalization.

Quercetin Interrupts the Positive Feedback Loop Between STAT3 and IL-6, Promotes Autophagy, and Reduces ROS, Preventing EBV-Driven B Cell Immortalization.

Journal: Biomolecules

Published: August 08, 2019

Targeting mutant p53 in cancer: the latest insights.

Targeting mutant p53 in cancer: the latest insights.

Journal: Journal of experimental & clinical cancer research : CR

Published: June 19, 2019

Autophagy manipulation as a strategy for efficient anticancer therapies: possible consequences.

Autophagy manipulation as a strategy for efficient anticancer therapies: possible consequences.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 30, 2019

Mutant p53, Stabilized by Its Interplay with HSP90, Activates a Positive Feed-Back Loop Between NRF2 and p62 that Induces Chemo-Resistance to Apigenin in Pancreatic Cancer Cells.

Mutant p53, Stabilized by Its Interplay with HSP90, Activates a Positive Feed-Back Loop Between NRF2 and p62 that Induces Chemo-Resistance to Apigenin in Pancreatic Cancer Cells.

Journal: Cancers

Published: April 30, 2019

Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression.

Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression.

Journal: Cancers

Published: April 16, 2019

Cytotoxic Drugs Activate KSHV Lytic Cycle in Latently Infected PEL Cells by Inducing a Moderate ROS Increase Controlled by HSF1, NRF2 and p62/SQSTM1.

Cytotoxic Drugs Activate KSHV Lytic Cycle in Latently Infected PEL Cells by Inducing a Moderate ROS Increase Controlled by HSF1, NRF2 and p62/SQSTM1.

Journal: Viruses

Published: November 12, 2018

The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells.

The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 14, 2015

Updates on HIPK2: a resourceful oncosuppressor for clearing cancer.

Updates on HIPK2: a resourceful oncosuppressor for clearing cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 23, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026